{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,11]],"date-time":"2026-03-11T23:35:33Z","timestamp":1773272133340,"version":"3.50.1"},"reference-count":24,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2020,10,27]],"date-time":"2020-10-27T00:00:00Z","timestamp":1603756800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"DOI":"10.3389\/fonc.2020.526716","type":"journal-article","created":{"date-parts":[[2020,10,27]],"date-time":"2020-10-27T05:00:33Z","timestamp":1603774833000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":12,"title":["Medullary Thyroid Carcinoma With Elevated Serum CEA and Normal Serum Calcitonin After Surgery: A Case Report and Literature Review"],"prefix":"10.3389","volume":"10","author":[{"given":"Li","family":"Chen","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ke","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fuxin","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xianghui","family":"He","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2020,10,27]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1016\/s0039-6109(16)44183-6","article-title":"Advances in the diagnosis and treatment of medullary thyroid carcinoma","volume":"67","author":"Brunt","year":"1987","journal-title":"Surg Clin North Am"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1089\/thy.2000.10.919","article-title":"Normal preoperative calcitonin levels do not always exclude medullary thyroid carcinoma in patients with large palpable thyroid masses","volume":"10","author":"Redding","year":"2000","journal-title":"Thyroid"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1007\/s11864-000-0052-7","article-title":"Medullary thyroid cancer","volume":"1","author":"Kebebew","year":"2000","journal-title":"Curr Treat Options Oncol"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(1984)54:4<657::aid-cncr2820540412>3.0.co;2-v","article-title":"Relationship of tissue carcinoembryonic antigen and calcitonin to tumor virulence in medullary thyroid carcinoma. An immunohistochemical study in early, localized, and virulent disseminated stages of disease","volume":"54","author":"Mendelsohn","year":"1984","journal-title":"Cancer"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2011.38.7639","article-title":"Completing the Arc: targeted inhibition of RET in medullary thyroid cancer","volume":"30","author":"Houvras","year":"2012","journal-title":"J Clin Oncol"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2005-0044","article-title":"Prognostic impact of serum calcitonin and carcinoembryonic antigen doubling-times in patients with medullary thyroid carcinoma","volume":"90","author":"Barbet","year":"2005","journal-title":"J Clin Endocrinol Metab"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1210\/jcem-19-1-152","article-title":"Medullary (solid) carcinoma of the thyroid; a clinicopathologic entity","volume":"19","author":"Hazard","year":"1959","journal-title":"J Clin Endocrinol Metab"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1016\/j.clon.2010.05.002","article-title":"Medullary thyroid carcinoma","volume":"22","author":"Pacini","year":"2010","journal-title":"Clin Oncol (R Coll Radiol)"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1097\/00005792-198411000-00001","article-title":"Medullary carcinoma of the thyroid. A study of the clinical features and prognostic factors in 161 patients","volume":"63","author":"Saad","year":"1984","journal-title":"Medicine"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1016\/j.surg.2011.09.043","article-title":"Preoperative basal calcitonin and tumor stage correlate with postoperative calcitonin normalization in patients undergoing initial surgical management of medullary thyroid carcinoma","volume":"150","author":"Yip","year":"2011","journal-title":"Surgery"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1586\/14737140.7.6.877","article-title":"Medullary thyroid carcinoma: surgical treatment advances","volume":"7","author":"Dionigi","year":"2007","journal-title":"Expert Rev Anticancer Ther"},{"key":"B12","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1089\/thy.2008.0403","article-title":"Medullary thyroid cancer: management guidelines of the American Thyroid Association","volume":"19","author":"Kloos","year":"2009","journal-title":"Thyroid"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2796.2003.01166.x","article-title":"Surgical treatment of medullary thyroid carcinoma","volume":"253","author":"Cohen","year":"2003","journal-title":"J Intern Med"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2009-2368","article-title":"Biomarker-based risk stratification for previously untreated medullary thyroid cancer","volume":"95","author":"Machens","year":"2010","journal-title":"J Clin Endocrinol Metab"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1515\/cclm-2015-0058","article-title":"Serum calcitonin negative medullary thyroid carcinoma: a systematic review of the literature","volume":"53","author":"Trimboli","year":"2015","journal-title":"Clin Chem Lab Med"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1007\/s00432-016-2169-5","article-title":"Clinical challenges with calcitonin-negative medullary thyroid carcinoma","volume":"142","author":"Sam\u00e0","year":"2016","journal-title":"J Cancer Res Clin Oncol"},{"key":"B17","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1089\/thy.2014.0335","article-title":"Revised American Thyroid Association guidelines for the management of medullary thyroid carcinoma","volume":"25","author":"Wells","year":"2015","journal-title":"Thyroid"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1089\/105072504323150813","article-title":"Lack of elevated serum carcinoembryonic antigen and calcitonin in medullary thyroid carcinoma","volume":"14","author":"Bockhorn","year":"2004","journal-title":"Thyroid"},{"key":"B19","doi-asserted-by":"publisher","first-page":"294","DOI":"10.1089\/thy.2012.0236","article-title":"Prevalence and clinical spectrum of nonsecretory medullary thyroid carcinoma in a series of 839 patients with sporadic medullary thyroid carcinoma","volume":"23","author":"Frank-Raue","year":"2013","journal-title":"Thyroid"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1530\/EJE-14-0076","article-title":"Small medullary thyroid carcinoma: post-operative calcitonin rather than tumour size predicts disease persistence and progression","volume":"171","author":"Saltiki","year":"2014","journal-title":"Eur J Endocrinol"},{"key":"B21","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1111\/j.1365-2265.2004.02037.x","article-title":"Medullary thyroid carcinoma","volume":"61","author":"Leboulleux","year":"2004","journal-title":"Clin Endocrinol (Oxf)"},{"key":"B22","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1001\/archsurg.142.3.289","article-title":"Abnormal carcinoembryonic antigen levels and medullary thyroid cancer progression: a multivariate analysis","volume":"142","author":"Machens","year":"2007","journal-title":"Arch Surg"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1210\/jcem.85.5.6601","article-title":"Improved diagnostic methods in the follow-up of medullary thyroid carcinoma by highly specific calcitonin measurements","volume":"85","author":"Engelbach","year":"2000","journal-title":"J Clin Endocrinol Metab"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1111\/dme.13437","article-title":"No calcitonin change in a person taking dulaglutide diagnosed with preexisting medullary thyroid cancer","volume":"35","author":"Sherman","year":"2018","journal-title":"Diabet Med"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2020.526716\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,10,27]],"date-time":"2020-10-27T05:00:34Z","timestamp":1603774834000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2020.526716\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,10,27]]},"references-count":24,"alternative-id":["10.3389\/fonc.2020.526716"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2020.526716","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,10,27]]},"article-number":"526716"}}